BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/16/2026 11:31:18 AM | Browse: 2 | Download: 0
 |
Received |
|
2025-07-02 02:00 |
|
Peer-Review Started |
|
2025-07-02 02:00 |
|
First Decision by Editorial Office Director |
|
2025-09-12 07:01 |
|
Return for Revision |
|
2025-09-12 07:01 |
|
Revised |
|
2025-09-25 22:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-08 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-08 07:37 |
|
Articles in Press |
|
2025-12-08 07:37 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-09 05:56 |
|
Publish the Manuscript Online |
|
2026-01-16 11:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sara Ascari, Rusi Chen, Andrea De Sinno, Bernardo Stefanini, Matteo Cescon, Matteo Serenari, Cristina Mosconi and Francesco Tovoli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francesco Tovoli, Associate Professor, MD, Division of Internal Medicine, Hepatobiliary and Immunoallergic Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna 40138, Emilia-Romagna, Italy. francesco.tovoli2@unibo.it |
| Key Words |
Hepatocellular carcinoma; Immune checkpoint inhibitors; Second-line therapy; Post-immunotherapy progression; Tyrosine kinase inhibitors; Bispecific antibodies; Adoptive T-cell therapy; Chimeric antigen receptor-T cells; Treatment sequencing; Clinical trials |
| Core Tip |
Patients with hepatocellular carcinoma progressing after frontline immunotherapy represent an emerging clinical challenge. This review critically explores the current second-line strategies under investigation, including tyrosine kinase inhibitors, novel immune checkpoint inhibitor-based regimens, bispecific antibodies, and adoptive T-cell therapies. Most approaches are supported by strong biological rationale, although high-quality comparative data are still lacking. The multiplicity of ongoing trials underscores the need for a better understanding of resistance mechanisms and therapeutic sequencing. This review may assist clinicians and researchers in interpreting the evolving landscape and in identifying future directions for personalized, effective post-immunotherapy management. |
| Publish Date |
2026-01-16 11:31 |
| Citation |
Ascari S, Chen R, De Sinno A, Stefanini B, Cescon M, Serenari M, Mosconi C, Tovoli F. Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials. World J Gastroenterol 2026; 32(3): 111528 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i3/111528.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i3.111528 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
